Use of test
A B-cell lymphoma may exhibit multiple gene rearrangements involving the genes MYC and BCL2 or MYC and BCL6 (double hit), or MYC and BCL2 and BCL6 (triple hit). These rearrangements have prognostic implications.
Double and triple hit lymphomas have a poor prognosis.
This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.
Fluorescent in situ hybridisation (FISH) analysis, using probes to detect gene fusions/rearrangements involving the MYC, BCL2 and BCL6 genes.
Requesting the test
This test is usually requested by a haematologist or oncologist.
0.5 mL bone marrow in transport media or 10 mL blood in lithium heparin if clinically appropriate. Testing can also be performed on formalin-fixed, paraffin embedded (FFPE) lymph node tissue.
To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.
We recommend that the patient or another adult check the labelling of request forms and sample tubes.
2 business days.
Up to $255.
If more information is required, the requesting clinician can call our laboratory on (07) 3377 8573.
This test is not rebated by Medicare. The laboratory assumes that the patient or client has provided informed financial consent for the test.